Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | PTAFR | P25105 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.40 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954777 | 0.99 | FOLH1 (0.47) | FOLH1PTAFRMAPTCYP3A4GPR132 | |
| SCHEMBL6953443 | 0.90 | NLRP3 (0.45) | PTAFRMAPTCYP3A4FAAH | |
| SCHEMBL6952538 | 0.88 | FAAH (0.44) | FOLH1PTAFRMAPTCYP3A4FAAH | |
| SCHEMBL6949829 | 0.85 | FAAH (0.41) | FOLH1PTAFRMAPTCYP3A4FAAH | |
| SCHEMBL6358935 | 0.85 | FOLH1 (0.49) | FOLH1PTAFRMAPTCYP3A4GPR132 | |
| SCHEMBL6949090 | 0.81 | LMNA (0.45) | FOLH1GPR132EPHX2CMKLR2CMKLR1 | |
| SCHEMBL4924109 | 0.81 | ITGB3 (0.52) | PTAFRTBXAS1 | |
| SCHEMBL6947579 | 0.80 | ITGB3 (0.51) | PTAFRMAPTCYP3A4TBXAS1 | |
| SCHEMBL29538593 | 0.78 | GPR132 (0.50) | FOLH1CYP3A4GPR132CMKLR2CMKLR1 | |
| SCHEMBL6950494 | 0.78 | ITGB3 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804418-B1 | PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 2003-03-26 | — | — | EP | claimed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | FOLH1 2015/4885PTAFR 72/4885MAPT 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.